Sign in

CIK 0001815442

  • Large accelerated filer

Kymera Therapeutics, Inc.

Sign in to watch
Ticker
KYMR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
812992166
Phone
+1 857-285-5314
Business address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
Former names
Kymera Therapeutics, Inc.
  1. 4 Planned sale Director sold 5,000 shares at an average $89.76 ($448,823)
  2. 4 Planned sale Chief Executive Officer sold 100,000 shares at $89.17 ($8,917,000)
  3. 4 Planned sale Chief Medical Officer sold 49,307 shares at an average $88.67 ($4,371,833)
  4. 4 Planned sale Chief Executive Officer sold 30,000 shares at an average $60.99 ($1,829,737)
  5. 4 Planned sale Chief Medical Officer sold 59,576 shares at an average $61.42 ($3,659,254)
  6. 4 Planned sale Chief Medical Officer sold 3,114 shares at $60.00 ($186,840)
  7. 4 Planned sale Director sold 5,000 shares at $59.19 ($295,949)
  8. 4 Planned sale Chief Financial Officer sold 79,220 shares at $50.00 ($3,961,380)
  9. 4 Planned sale Chief Executive Officer sold 30,000 shares at $49.00 ($1,470,000)
  10. 4 Grant or award Chief Legal Officer acquired 52,500 shares (grant or award)
  11. 3 Insider Initial Statement of Ownership
  12. 4 Open-market buy Director bought 317,167 shares at $44.00 ($13,955,348)
  13. 4 Open-market buy Director bought 655,500 shares at $44.00 ($28,842,000)
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 4 of 15 · 296 filings